On November 5, 2019 Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, reported third quarter 2019 financial results and provided a corporate update (Press release, Kura Oncology, NOV 5, 2019, View Source [SID1234550330]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We continue to be very encouraged by our growing body of data that support the potential of tipifarnib, highlighted recently by impressive results from our ongoing Phase 2 trial in HRAS mutant head and neck squamous cell carcinomas (HNSCC)," said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology. "These data underscore the activity of tipifarnib in this difficult-to-treat patient population, and we believe they increase the probability of success of our registrational strategy in HRAS mutant HNSCC. We continue to execute on our AIM-HN registration-directed trial, which, if positive, will establish tipifarnib as a first-in-class farnesyl transferase inhibitor for patients with cancer. In addition, we look forward to additional data later this year from our ongoing Phase 2 trial in angioimmunoblastic T-cell lymphoma (AITL), an indication for which we are seeking regulatory feedback regarding next steps."

"Meanwhile, we continue to make steady and encouraging progress with our emerging pipeline programs," Dr. Wilson continued, "including continued dose escalation of our ERK inhibitor, KO-947, and the initiation of a Phase 1 trial of our first-in-class menin-MLL inhibitor, KO-539, in patients with relapsed or refractory acute myeloid leukemia (AML). We believe both of our early-stage drug candidates represent differentiated approaches that could potentially address large indications with high unmet need, and we look forward to sharing updates on all of our progress in the months ahead."

Recent Highlights

Durable anti-tumor activity in Phase 2 trial of tipifarnib in HRAS mutant HNSCC – Last week, Kura reported updated data from its RUN-HN Phase 2 trial of tipifarnib in HNSCC patients with high HRAS mutant variant allele frequency at the AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper) in Boston. The preliminary results showed that 10 of the 18 efficacy-evaluable patients achieved a confirmed partial response (PR), for an objective response rate of 56%. In addition, eight patients experienced disease stabilization, including two who achieved an unconfirmed PR, one of whom was awaiting a confirmatory response assessment as of the data cutoff date. The median progression-free survival (PFS) of the 18 evaluable patients treated with tipifarnib was 6.1 months, compared to 2.8 months on their last prior therapy, including 8.3 months among patients who achieved a PR on tipifarnib and 4.5 months for those with stable disease. Patients had a median of two prior lines of therapy (range 0-6), with no responses observed on their last prior therapy.

Updated Phase 2 data support enrichment strategy in ongoing registration-directed trial – Of the eight efficacy-evaluable patients in the RUN-HN Phase 2 trial who were prospectively enrolled with high HRAS mutant variant allele frequency, three achieved a confirmed PR and five had stable disease, including two who achieved an unconfirmed PR, one of whom is awaiting a confirmatory response assessment. Kura’s registration-directed trial, AIM-HN, is designed to enroll at least 59 evaluable HNSCC patients with high HRAS mutant variant allele frequency who have received prior platinum-based therapy. AIM-HN was initiated in November 2018 and is now open in more than 75 clinical sites worldwide. The trial is expected to require approximately two years for full enrollment. Based upon the statistical assumptions, AIM-HN could be positive as soon as 15 responses are confirmed.

Positive Phase 2 trial of tipifarnib in HRAS mutant urothelial carcinoma – In September 2019, Kura reported that an investigator-sponsored Phase 2 trial of tipifarnib in HRAS mutant urothelial carcinomas met its primary efficacy endpoint prior to completion of enrollment. The trial is being conducted at the Samsung Medical Center in Seoul, South Korea. Five of the 13 evaluable patients experienced confirmed objective responses, with four patients having experienced PFS of greater than 6 months. Further analyses of the trial are ongoing, and data are expected to be presented at a medical meeting next year.

Data from Phase 2 trial of tipifarnib in AITL accepted for oral presentation at ASH (Free ASH Whitepaper). In June 2019, Kura announced that the primary endpoint was achieved in both expansion cohorts in its Phase 2 trial of tipifarnib in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). Additional data, including new patients from the AITL expansion cohort, have been accepted for oral presentation at the upcoming American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting in December 2019.

Expanded patent exclusivity for tipifarnib – In September 2019, the U.S. Patent and Trademark Office issued a new patent further extending Kura’s exclusivity to the use of any farnesyl transferase inhibitor (FTi) for the treatment of CXCL12-expressing PTCL and AML. This adds to the Company’s growing portfolio of patents involving CXCL12 pathway biomarkers and follows the issuance of another patent earlier this year that covers the use of any FTi for the treatment of HRAS mutant HNSCC. These new patents expire in 2037 and 2036, respectively, excluding any possible patent term extension. The Company continues to aggressively pursue additional intellectual property protection, both in the U.S. and abroad.

Initiated Phase 1 trial of KO-539 in relapsed or refractory AML – In September 2019, the first patient was dosed in a Phase 1 trial of KO-539, Kura’s first-in-class, potent and selective small molecule inhibitor of the menin-mixed lineage leukemia (menin-MLL) interaction. The Phase 1, open-label, dose-escalation trial is designed to determine the recommended Phase 2 dose or maximum tolerated dose of KO-539 in patients with relapsed or refractory AML. Upon completion of the dose-escalation portion of the trial, expansion cohorts are planned to further assess the safety and activity of KO-539 in specific genetic subgroups, such as patients with MLL fusions or partial tandem duplications and patients with mutations in the NPM1 oncogene.

Strengthened senior leadership team and board of directors – Kura recently added Kathleen Ford as Chief Operating Officer, James Basta as Chief Legal Officer and Diane Parks as a member of the board of directors. Previously, Ms. Ford was Senior Vice President, Head of Global Clinical Operations at Merck Serono, a division of Merck KGaA, Mr. Basta was Senior Vice President, Chief Corporation Counsel at Biogen, and Ms. Parks was most recently Senior Vice President, Head of U.S. Commercial at Kite Pharma. All three are valuable additions to Kura, as the Company continues to advance its three clinical-stage oncology assets and begins to focus on commercial readiness.
Financial Results

Research and development expenses for the third quarter of 2019 were $12.5 million, compared to $11.7 million for the third quarter of 2018.

General and administrative expenses for the third quarter of 2019 were $5.1 million, compared to $4.3 million for the third quarter of 2018.

Net loss for the third quarter of 2019 was $16.4 million, or $0.36 per share, compared to $15.0 million, or $0.40 per share, for the third quarter of 2018.

Cash, cash equivalents and short-term investments totaled $250.1 million as of September 30, 2019, compared with $179.0 million as of December 31, 2018.

Management continues to expect that current cash, cash equivalents and short-term investments will be sufficient to fund current operations into the second half of 2021.
Upcoming Milestones

Additional data from the AITL expansion cohort in the ongoing Phase 2 trial of tipifarnib in PTCL at ASH (Free ASH Whitepaper) in December 2019

Regulatory feedback from the Phase 2 trial of tipifarnib in AITL in the first half of 2020

Additional data from the ongoing Phase 2 trial of tipifarnib in chronic myelomonocytic leukemia (CMML) in the first half of 2020

Initiation of a proof-of-concept study of tipifarnib in pancreatic cancer in 2020

Data from the Phase 2 investigator-sponsored trial of tipifarnib in urothelial carcinoma in 2020

Potential for full enrollment in the AIM-HN registration-directed trial of tipifarnib in HRAS mutant HNSCC by the end of 2020

Completion of the dose-escalation portion of the Phase 1 trial of KO-947 by the end of 2019 or early 2020

Initiation of tumor-specific extension cohort(s) in the Phase 1 trial of KO-947 in 2020

Achievement of a recommended Phase 2 dose in the Phase 1 dose-escalation trial of KO-539 in 2020
Conference Call and Webcast

Kura’s management will host a webcast and conference call today at 4:30 p.m. ET / 1:30 p.m. PT, November 5, 2019, to discuss the financial results for the third quarter 2019 and provide a corporate update. The live call may be accessed by dialing (877) 516-3514 for domestic callers and (281) 973-6129 for international callers and entering the conference code: 5159117. A live webcast of the call will be available from the Investors and Media section of the Company’s website at www.kuraoncology.com, and a replay will be available shortly after the live event.

On November 5, 2019 Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, reported presentations on two ongoing clinical programs, JTX-4014 and vopratelimab, at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) 34th Annual Meeting, being held November 6-10, 2019 in National Harbor, Maryland (Press release, Jounce Therapeutics, NOV 5, 2019, View Source [SID1234550329]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Our poster sessions at this year’s SITC (Free SITC Whitepaper) conference demonstrate the progress we have made to date on both of our clinical-stage programs, vopratelimab, an ICOS agonist, and JTX-4014, a PD-1 inhibitor. We have previously shown the relationship between the vopratelimab-associated emergence of ICOS hi CD4 T cells and clinical benefit," said Elizabeth Trehu, M.D., chief medical officer of Jounce Therapeutics. "The EMERGE trial builds on the biology of induction of ICOS hi CD4 T cells by ipilimumab and their expansion and sustained activation by vopratelimab. We will provide the scientific rationale for the unique dosing and sequencing strategy of ipilimumab and vopratelimab in EMERGE, which we believe optimizes ICOS hi CD4 T cell priming and agonist biology. In a separate poster at SITC (Free SITC Whitepaper), the safety and preliminary efficacy data for JTX-4014 being presented supports the use of this PD-1 inhibitor in combination with our other product candidates."

Poster Presentation Details:

Title: Phase 1 First in Human Study of Programmed Cell Death Receptor-1(PD-1) Inhibitor Monoclonal Antibody (mAb) JTX-4014 in Adult Subjects with Advanced Refractory Solid Tumor Malignancies
Presentation Date and Time: Friday, November 8, 2019, 7:00am – 8:00pm ET
Presenter: Kyriakos P. Papadopoulos, M.D.
Abstract ID: P439

Jounce researchers describe the safety, preliminary efficacy and recommended Phase 2 doses for JTX-4014 including:

Acceptable safety profile for JTX-4014 based on a 6-cohort dose-escalation trial. There were no deaths or dose limiting toxicities, few Grade 3/4 adverse events and the only related serious adverse event (SAE) was pneumonitis, which occurred after the second dose at 1200 mg Q3W.
Antitumor activity observed with an overall response rate of 16.7% (3/18), including 1 complete response and 2 partial responses (confirmed) in a difficult to treat population with no therapeutic options.
The disease control rate was 44.4% (8/18).
Typical IgG4 profile with linear pharmacokinetics (PK).
Planned Phase 2 studies utilizing recommended doses of either 500mg Q3W or 1000mg Q6W.
Title: Phase 2 Multicenter Trial of ICOS Agonist Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Adult Subjects with Non-Small Cell Lung Cancer or Urothelial Cancer (EMERGE)
Presentation Date and Time: Saturday, November 9, 2019, 7:00am – 8:30pm ET
Presenter: Russell K. Pachynski, M.D.
Abstract ID: P438

Jounce researchers highlight the scientific rationale for the ongoing Phase 2 EMERGE trial including:

Based on reverse translational findings from the ICONIC trial, strategies to optimize emergence and expansion of ICOS hi CD4 T cells have become a cornerstone of the vopratelimab development program.
The sequence of administration of ipilimumab and vopratelimab combination in EMERGE is designed to induce ICOS hi CD4 T cells with ipilimumab followed by their expansion and sustained activation by vopratelimab.
A pulsed dose and schedule for vopratelimab, designed to optimize agonist antibody activity, is explored. Specifically, the trial evaluates two different vopratelimab dose levels and a new dosing interval.
Both posters will be available on the "Our Pipeline" section of the Jounce Therapeutics website under "Publications" at www.jouncetx.com.

About Vopratelimab
Jounce’s lead product candidate, vopratelimab (formerly JTX-2011), is a clinical-stage monoclonal antibody that binds to and activates ICOS, the Inducible T cell CO Stimulator, a protein on the surface of certain T cells commonly found in many solid tumors. Vopratelimab was previously assessed in the Phase 1/2 ICONIC trial and was found to be safe and well-tolerated, alone and in combination with each of the anti-PD-1 antibodies nivolumab and pembrolizumab, and ipilimumab, an antibody that binds to CTLA-4. In June 2018, Jounce reported Response Evaluation Criteria in Solid Tumors (RECIST) responses and other tumor reductions as determined by investigator assessment that were associated with an ICOS pharmacodynamic biomarker, ICOS hi CD4 T cells. In April 2019, Jounce reported data on patients in the ICONIC trial with the emergence of ICOS hi CD4 T cells who had improved progression free survival and overall survival compared to patients with ICOS lo CD4 T cells; this was based on an analysis of a subgroup of patients with multiple solid tumor types including PD-1 inhibitor naive and PD-1 inhibitor experienced patients. Vopratelimab is currently being assessed in the Phase 2 EMERGE clinical trial in combination with ipilimumab in patients with non-small cell lung cancer or urothelial cancer who have progressed on or after PD-1/PD-L1 inhibitor therapies.

About JTX-4014
JTX-4014 is a well-characterized fully human IgG4 monoclonal antibody designed to block binding to PD-L1 and PD-L2. Jounce is developing JTX-4014 for potential use in combination with its pipeline of future product candidates. Jounce completed enrollment in the Phase 1 clinical trial of JTX-4014 and additional studies with JTX-4014 with our other product candidates are planned.

On November 5, 2019 Inovio Pharmaceuticals, Inc. (NASDAQ: INO) reported positive interim results from Inovio’s Phase 2 study (NCT03491683) of newly diagnosed glioblastoma multiforme (GBM) combining Inovio’s INO-5401, a T cell-activating immunotherapy encoding for three tumor-associated antigens (hTERT, WT1, and PSMA), and INO-9012, an immune activator encoding IL-12, in combination with Libtayo (cemiplimab), a PD-1 blocking antibody developed by Regeneron Pharmaceuticals (NASDAQ: REGN) in collaboration with Sanofi (Press release, Inovio, NOV 5, 2019, View Source [SID1234550328]). The data will be featured in a late-breaking poster presentation at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 2019 Annual Meeting in National Harbor, Maryland, November 6-10.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Key interim data from the 52-patient clinical trial showed that 80% (16 of 20) of MGMT gene promoter methylated patients and 75% (24 of 32) of unmethylated patients were progression-free at six months (PFS6) measured from the time of their first dose, substantially exceeding historical standard-of-care data.

This immunotherapy combination with a PD-1 checkpoint inhibitor also exhibited supportive safety, tolerability, and immunogenicity data and suggested an acceptable safety profile consistent with that of Libtayo and Inovio’s platform technology. The majority of patients tested had a T cell immune response to one or more tumor-associated antigens encoded by INO-5401. Immune responses to all three tumor-associated antigens were demonstrated in this study. Inovio plans to report 12- and 18-month overall survival data next year.

Dr. David Reardon, M.D., Coordinating Principal Investigator of the study and the Clinical Director for Neuro-Oncology at the Dana-Farber Cancer Institute, said, "This innovative trial provides promising information that the combination of INO-5401 plus INO-9012, a T cell-promoting therapy, combined with Libtayo, a checkpoint inhibitor, may provide clinically meaningful benefit in this very difficult to treat disease."

Dr. J. Joseph Kim, Inovio’s President & CEO, said, "Our new data demonstrates the potential of our immunotherapies utilizing tumor-associated antigens in cancer treatments. Our goal in this GBM trial is to increase progression-free and overall survival of patients facing a disease where neither the standard of care nor clinical outcomes have significantly advanced in decades. Previously, other checkpoint inhibitor treatment alone in GBM trials did not show any meaningful clinical benefit over standard of care. However, the addition of INO-5401 and its ability to generate antigen-specific T cells demonstrated early efficacy signals in progression-free survival. We look forward to reporting additional data including overall survival at months 12 and 18 from the trial in the coming year."

Poster Details

Poster 858:

An Open-Label, Multi-center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination with Cemiplimab in Subjects with Newly-Diagnosed Glioblastoma (GBM)

Category:

Late-Breaker

Date/Time:

Friday, Nov. 8th, 12:30 – 2 p.m. and Saturday, Nov. 9th 12:35 – 2:05 p.m.

Location:

Displayed in the Potomac Foyer (outside the Plenary session room, Potomac Ballroom)

Study Design

The trial was designed to evaluate safety, immunogenicity and preliminary efficacy of INO-5401 and INO-9012 in combination with Libtayo, with radiation and chemotherapy, in subjects with newly-diagnosed glioblastoma (GBM). This is a Phase 1/2, open-label, multi-center trial conducted in 52 evaluable patients with GBM. There were 2 cohorts in this trial. Cohort A were participants with a tumor with an unmethylated O6-methylguanine-deoxyribonucleic acid (DNA) methyltransferase (MGMT) promoter. Cohort B included participants with a tumor with a MGMT methylated promoter or who have indeterminate MGMT status. Both cohorts received INO-5401 and INO-9012 and Libtayo at the same doses and on the same dosing schedule, and both cohorts received radiation and temozolomide (TMZ), if clinically indicated. Interim data presented here and at SITC (Free SITC Whitepaper) was obtained as of October 2019 and final study data is expected in Q4 2020. For more information of the clinical study, see www.clinicaltrials.gov, identifier NCT03491683.

About Glioblastoma Multiforme (GBM)

GBM is the most common and aggressive type of brain cancer and remains a devastating disease for both patients and caregivers. Its prognosis is extremely poor, despite a limited number of new therapies approved over the last 10 years. The median overall survival for patients receiving standard of care therapy is approximately 15 months and the median progression-free survival is approximately 7 months. In the U.S., the estimated annual incidence of GBM is 11,362 cases or 3.21 cases per 100,000 persons and the median age at diagnosis is 65 years.

About INO-5401 and INO-9012

INO-5401 encodes for Inovio’s SynCon antigens for hTERT, WT1, and PSMA, and has the potential to be a powerful cancer immunotherapy in combination with checkpoint inhibitors. The National Cancer Institute previously highlighted hTERT, WT1, and PSMA among a list of important cancer antigens, designating them as high priorities for cancer immunotherapy development. These three antigens were reported to be over-expressed, and often mutated, in a variety of human cancers, and targeting these antigens may prove efficacious in the treatment of patients with cancer. INO-9012 encodes for IL-12, which is a T cell immune activator.

On November 5, 2019 IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage biopharmaceutical company pioneering a novel class of immunotherapies, reported that translational data, including comprehensive immune profiling of clinical samples from subjects treated with IMV’s lead compound, DPX-Survivac, will be presented during the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper), being held on November 6 – 10, 2019 in National Harbor, MD (Press release, IMV, NOV 5, 2019, View Source [SID1234550327]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In connection with DeCidE1, IMV’s ongoing Phase 1b/2 study of DPX-Survivac in advanced recurrent ovarian cancer, the Company conducted immune-profiling of peripheral blood mononuclear cell (PBMC) and tumor samples to evaluate the program’s underlying mechanism of action. The data suggest that the treatment regimen per the study protocol induced robust and sustained survivin-specific T cell responses from nearly all evaluable subjects and T cell infiltration into tumors without loss of functionality. Specifically, a comparison of T cell receptor ²-chain repertoire analyses between pre- and on-treatment tumor biopsies shows new clonotypes can represent up to 90% of the intratumoral T cell population.

"We are very pleased to present these translational clinical data in advanced recurrent ovarian cancer at this important scientific venue. Taken together with earlier data, this comprehensive analysis continues to validate our new T cell therapy mechanism," said Frederic Ors, President and Chief Executive Officer at IMV. "We find these data highly encouraging, as they highlight some of the key distinctive features of our promising new treatment for patients with this hard-to-reach cancer, as well as for patients with one of the numerous other tumor types that express survivin. We look forward to demonstrating how this effect translates into patient benefits with upcoming topline data from this study."

Poster Presentation Details:

Poster Title: Comprehensive immune profiling of clinical samples from subjects with advanced recurrent epithelial ovarian cancer treated with a novel T cell activating therapy, DPX-Survivac

Presenter: Brennan S. Dirk, PhD – IMV Inc, Dartmouth, Nova Scotia

Abstract Number: P586

Date and Time: Poster will be displayed all day on Nov. 9, 2019, 7:00 am – 8:30 pm EST

Location: Poster Hall (Prince George AB)

SITC has published the official abstracts on its meeting website in advance of the SITC (Free SITC Whitepaper) Annual Meeting. The poster will be available under Events, Webcasts and Presentations in the investors section of IMV’s website on the day of presentation.

About DPX-Survivac

DPX-Survivac is the lead candidate in IMV’s new class of immunotherapies that program targeted T cells in vivo. It has demonstrated the potential for targeted, persistent, and durable T cell generation. IMV believes this mechanism of action (MOA) is key to generating durable solid tumor regressions. DPX-Survivac consists of survivin-based peptides formulated in IMV’s proprietary DPX drug delivery platform. DPX-Survivac is designed to work by eliciting a CD8+ T cell immune response against cancer cells presenting survivin peptides on their surface.

Survivin, recognized by the National Cancer Institute (NCI) as a promising tumor-associated antigen, is broadly over-expressed in most cancer types, and plays an essential role in antagonizing cell death, supporting tumor-associated angiogenesis and promoting resistance to chemotherapies. IMV has identified over 20 cancer indications in which survivin can be targeted by DPX-Survivac.

DPX-Survivac has received Fast Track designation from the U.S. Food and Drug Administration (FDA) as maintenance therapy in advanced ovarian cancer, as well as orphan drug designation status from the U.S. FDA and the European Medicines Agency (EMA) in the ovarian cancer indication.

On November 5, 2019 Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, reported preclinical and clinical data demonstrating that ATLAS can identify relevant neoantigens and exclude inhibitory neoantigens that suppress anti-tumor immune responses at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper), taking place from November 6 – 10, 2019 in National Harbor, Maryland (Press release, Genocea Biosciences, NOV 5, 2019, View Source [SID1234550326]). ATLAS is Genocea’s unique platform that profiles each patient’s T cell responses to every candidate neoantigen to select those driving pre-existing anti-tumor responses. Additional data will also be presented, demonstrating that inhibitory neoantigen profiles may predict if a patient will respond to immunotherapy and confirming broad immune response data for the company’s novel neoantigen therapy GEN-009.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Our preclinical findings represent exciting and powerful new discoveries in the role that inhibitory neoantigens play in response to immunotherapies," said Tom Davis, M.D., Chief Medical Officer, Genocea. "Through these data, we demonstrate the power of the ATLAS platform to identify and target only those neoantigens with a high propensity to drive anti-tumor responses while excluding inhibitory, immunosuppressive antigens. We are also pleased to share additional GEN-009 results, which round out the GEN-009 clinical immunogenicity data set from our initial patient cohort and confirm the relevance of these preclinical findings in advancing patient treatment."

The following posters will be located in Prince George’s Exhibition Halls AB. Odd-numbered posters will be presented on Friday, November 8th from 12:30 – 2:00 p.m. ET and 6:30 – 8:00 p.m. ET, and even-numbered posters will be presented on Saturday, November 9th from 12:35 – 2:05 p.m. ET and 7:00 – 8:30 p.m. ET.

Summary of Poster #P678 – Vaccine neoantigens empirically identified through the ex vivo ATLAS platform promote potent therapeutic responses to cancer in mice

ATLAS screening of mutations from B16F10 melanoma identified approximately 4 percent of mutations as neoantigens, and 3.5 percent of mutations as eliciting potentially deleterious inhibitory T cell responses; the majority were not algorithm-predicted.

When an ATLAS-identified stimulatory neoantigen was combined in a vaccine formulation and therapeutically administered as monotherapy into tumor-bearing mice, tumor growth was either significantly delayed or completely abrogated in all mice.

Vaccination with inhibitory neoantigens suppresses anti-tumor immune responses.

Summary of Poster #P417 – ATLAS identifies relevant neoantigens for therapeutic anti-tumor vaccination and may serve as a biomarker for efficacy of immunotherapy of solid tumors

In an analysis of the first six patients who participated in the GEN-009 phase 1/2a study, ATLAS identified neoantigens by recalling both stimulatory and inhibitory neoantigen-specific T cell responses; many of which were not predicted using in silico approaches.

Post-vaccination predicted neoantigens were not more immunogenic than not predicted neoantigens.

In a separate analysis including non-vaccinated subjects, the proportion of inhibitory to stimulatory neoantigen-specific responses may be a biomarker of immunotherapy success.

Summary of Poster #P420 – Broad immunogenicity from GEN-009, a neoantigen vaccine using ATLAS, an autologous immune assay, to identify immunogenic and inhibitory tumor neoantigens

GEN-009-101 is a phase 1/2a study testing safety, immunogenicity and clinical activity in immune responsive tumors (NCT03633110).

The vaccine was well-tolerated with only grade 1/2 adverse events reported.

With data from patients enrolled (n=5), vaccination elicited both CD8+ and CD4+ T cell responses in all subjects, as measured by ex vivo and in vitro stimulation fluorospot assays, and confirms broad immune responses generated against 98 percent of all immunized neoantigens with a range of tumor types.